Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of Sacituzumab govitecan in Metastatic Urothelial Cancer After Platinum or Anti-PD-1/PD-L1 Failure
2018-001167-23Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- Nov 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in transitional cell carcinoma (TCC) and Renal pelvis urothelial carcinoma (UTUC), sponsored by Gilead Sciences. Primary endpoint: Objective Response Rate (ORR). Started Nov 2018; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
transitional cell carcinoma (TCC)Renal pelvis urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2018-001167-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001167-23.